Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Skin Diseases 1Rare Diseases 1Polycystic Ovary Syndrome 1Endocrine System Diseases 1Advanced Malignant Neoplasm 1Acanthosis Nigricans 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Spironolactone × Clear all
NCT01867294 2020-01-09

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Academic and Community Cancer Research United

Phase 2 Completed
19 enrolled 9 charts
Other neoplasm

Advanced Malignant Neoplasm

NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡